Tecvayli

United Kingdom · access guide

Tecvayli access in the United Kingdom: the Specials Licence pathway

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Tecvayli (teclistamab) is the first BCMA-directed CD3 bispecific T-cell engager antibody, from Janssen, FDA-approved in October 2022 and granted UK marketing authorisation by the MHRA. NICE issued TA841 in late 2022 recommending Tecvayli for relapsed and refractory multiple myeloma after at least three prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, within an NHS England managed access agreement. The medicine is delivered through a step-up dosing protocol with mandatory inpatient initiation for CRS monitoring, then weekly subcutaneous administration, with a transition to every-two-weeks dosing now incorporated in the UK SmPC for patients with sustained response.

The UK access pattern for Tecvayli is similar to other bispecific T-cell engagers: NHS funding is in place within NICE-recommended criteria, the bottleneck is centre capacity for the step-up dosing phase, and private supply via the Specials route handles cases sitting outside the NHS eligibility threshold or pursuing parallel routes.

Why UK myeloma patients pursue Tecvayli

Patients with triple-class refractory myeloma face a poor prognosis without effective subsequent therapy. Tecvayli has demonstrated overall response rates of approximately 63% in the MajesTEC-1 registration trial in this heavily pre-treated population, with median progression-free survival in the 11 to 12 month range and substantial duration of response in patients who respond. UK haematologists view Tecvayli as a foundational therapy in the relapsed/refractory setting, with the choice between Tecvayli, Talvey, and the BCMA-directed CAR-T options depending on patient-specific factors.

UK access friction includes the centre slot for step-up dosing initiation, the local haematology service's familiarity with bispecific antibody management, and the NICE eligibility threshold which may exclude clinically appropriate patients sitting at or near the boundary. Private supply through the Specials route handles these cases.

The Specials Licence pathway for Tecvayli in the UK

Tecvayli holds UK marketing authorisation and is supplied through the Janssen UK specialty distribution chain to UK haematology centres. For patients outside the NICE-recommended criteria but clinically appropriate per their consultant's judgment, the Specials framework supports a private prescription. The supply chain follows the same Specials Licence holder route as other UK biologics, with the centre's step-up dosing protocol and CRS management infrastructure as the operational gating items rather than the documentation.

The step-up dosing protocol for Tecvayli typically runs three escalating subcutaneous doses (0.06 mg/kg, 0.3 mg/kg, then 1.5 mg/kg) over 2 to 4 days with at least 48 hours of monitoring after each step-up dose. Once the patient clears the step-up phase the maintenance weekly subcutaneous 1.5 mg/kg dosing can transition to outpatient delivery, and a recent label update allows transition to every-two-weeks dosing in patients with sustained response.

Where Tecvayli is delivered in the UK

UK haematology centres with bispecific antibody programmes deliver Tecvayli. The principal centres include King's College Hospital London, University College London Hospitals (UCLH), The Royal Marsden NHS Foundation Trust (with Royal Marsden Private Care), the Christie and Manchester Royal Infirmary cell therapy and myeloma programme, Newcastle upon Tyne Hospitals, the Queen Elizabeth Hospital Birmingham (University Hospitals Birmingham), Beatson West of Scotland Cancer Centre Glasgow, and Belfast City Hospital. For private patients HCA Healthcare UK at University College Hospital, The Royal Marsden Private Care, The London Clinic, and the Cromwell Hospital handle private bispecific antibody administration.

The dispensing pharmacy at the treating centre holds Tecvayli, tocilizumab and anti-IL-6 backup, corticosteroid supply for ICANS management, and the inpatient antibiotic and inotrope stock required for CRS escalation management.

Real cost picture for Tecvayli in the UK

Tecvayli's US WAC is approximately USD 40,000 per month at the weekly dosing schedule, or approximately USD 480,000 per year. At 0.79 GBP to 1 USD this converts to approximately GBP 378,000 per year for the medicine alone, before UK supply and fees. NHS contracted pricing under the managed access agreement reflects a confidential commercial discount. With the every-two-weeks dosing transition available for sustained responders, the annual cost for stable patients can drop materially after the first 6 to 12 months.

For private supply through a UK specialty pharmacy the price typically sits below US WAC equivalent depending on quantity and supplier. UK private medical insurance handles Tecvayli case by case with pre-authorisation; cover varies materially.

Typical timeline for Tecvayli in the UK

For an NHS-routed case the timeline runs as follows: referral to specialist myeloma centre, eligibility confirmation under TA841 criteria, baseline workup, step-up dosing admission (3 doses over approximately 7 to 10 days with monitoring), and transition to outpatient weekly maintenance dosing. Total from referral to first dose typically 4 to 12 weeks depending on centre capacity. For a Reserve Meds cross-border Specials case the US-side sourcing and documentation typically completes within 2 to 3 weeks; the UK haematology centre's step-up dosing slot is the operational rate-limiter.

What your UK haematology consultant needs to provide

The treating UK consultant haematologist with myeloma subspecialty expertise is the prescribing physician of record. The clinical packet typically includes the multiple myeloma diagnosis and stage, the prior therapy log demonstrating prior proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody exposure, the response status to the most recent line, current performance status, organ function panel, immunoglobulin levels (Tecvayli causes hypogammaglobulinaemia), CMV and other viral status, and the centre's CRS and ICANS management protocol.

Common questions about Tecvayli in the UK

Will the NHS fund Tecvayli? Yes, within the NICE TA841 recommendation and the NHS England managed access agreement for patients meeting the prior-therapy criteria.

How does Tecvayli compare to the BCMA-directed CAR-T options? Tecvayli is an off-the-shelf bispecific antibody that can begin immediately; the BCMA-directed CAR-T cell therapies (Carvykti, Abecma) require autologous apheresis and 4 to 6 weeks of manufacture but deliver a single one-time infusion with deeper responses. Tecvayli is continuous therapy weekly or every-two-weeks until progression. The choice depends on disease burden, fitness, organ function, and centre availability.

What is the every-two-weeks dosing transition? The Tecvayli SmPC has been updated to allow transition from weekly to every-two-weeks maintenance dosing in patients who have achieved a sustained response, reducing the treatment burden materially. Your haematologist makes the transition decision based on the depth and duration of response.

What about infection risk? Tecvayli causes profound hypogammaglobulinaemia and patients are at increased risk of serious infections. Standard practice includes IVIG replacement, pneumococcal and other vaccinations, antiviral and antifungal prophylaxis as appropriate, and CMV monitoring.

Will my UK private medical insurance cover Tecvayli? Major UK private medical insurers handle Tecvayli case by case with pre-authorisation. Some policies cover with annual specialty benefit caps that the treatment cost exceeds.

Where Reserve Meds fits in Tecvayli cases

Reserve Meds is a US-based concierge coordinator. For Tecvayli our role spans UK patients pursuing parallel routes outside NHS commissioning, documentation support across the multi-week step-up dosing and ongoing maintenance phases, and cross-market continuity of care. We do not replace your UK haematology consultant or the haematology centre's bispecific antibody programme.

The Yellow Card pharmacovigilance pathway for Tecvayli

The MHRA Yellow Card scheme is the UK's national pharmacovigilance reporting system. Healthcare professionals, patients, and carers can report suspected adverse drug reactions, medical device incidents, defective medicines, and counterfeit medicines through the scheme. For specialty medicines accessed through the Specials Licence pathway, Yellow Card reporting is the operational mechanism that connects the UK clinical experience back to the global pharmacovigilance dataset that the MHRA, FDA, EMA, and other regulators rely on.

For Tecvayli specifically, Reserve Meds coordinates the pharmacovigilance reporting chain in three ways. First, the prescribing UK consultant or the dispensing pharmacy submits any suspected adverse reactions through the Yellow Card scheme as standard practice. Second, the manufacturer's UK pharmacovigilance contact receives the case report through the standard regulatory channel and connects the case to the global safety database. Third, where the patient's clinical follow-up continues across markets, Reserve Meds provides the documentation continuity that lets the patient's consultants and the manufacturer's safety team coordinate across borders.

The MHRA also operates the Black Triangle (inverted black triangle) safety monitoring scheme for medicines that are under additional monitoring (typically newer medicines or medicines for which additional safety data are being collected). The Yellow Card scheme works the same way for Black Triangle medicines but with heightened attention to reporting.

UK consumer protection and patient rights for Tecvayli

UK patients accessing specialty medicines through private pharmacy supply have the same consumer protections that apply to any UK regulated medicine purchase. The Care Quality Commission regulates private healthcare providers in England; Healthcare Improvement Scotland, Healthcare Inspectorate Wales, and the Regulation and Quality Improvement Authority in Northern Ireland are the parallel regulators in the devolved nations. The General Pharmaceutical Council regulates pharmacy professionals and registered pharmacy premises. The General Medical Council regulates doctors. The Nursing and Midwifery Council regulates nurses, including specialist nurses involved in cell therapy and homecare administration.

For UK patients accessing Tecvayli, the relevant protections include the prescribing consultant's professional duty under GMC Good Medical Practice, the dispensing pharmacist's professional standards under General Pharmaceutical Council standards, the homecare provider's regulatory framework (where applicable), and the manufacturer's UK pharmacovigilance obligations. Reserve Meds operates as a US-based coordinator and is subject to US regulatory frameworks for our US-side operations; we do not replace or substitute for UK consumer protections, which the UK clinical and pharmacy chain provides directly.

Special considerations for international UK residents and dual-citizen families

The UK is home to a substantial population of international residents, dual-citizen families, and patients who spend significant time across multiple markets. For Tecvayli cross-border continuity of care across the UK, the United States, the Gulf, India, and other markets is a recurring operational pattern. Reserve Meds is structured to support this cross-market reality with a single coordinator who understands the regulatory frameworks across the relevant jurisdictions, the documentation portability across markets, and the operational connection back to the UK clinical team during periods of UK residence.

UK patients who spend time in the United States may also pursue treatment at a US authorised treatment centre when this is clinically or operationally preferable. Reserve Meds provides the US-side liaison, the documentation packet for the US treatment centre, and the operational support across the UK-US clinical handover both at the start and on return to the UK for long-term follow-up.

Where to read more about Tecvayli and the UK Specials pathway

Reserve Meds publishes detailed reference material across the regulatory pathways, country specifics, and condition-specific access guides. For the regulatory framework underlying the UK route to Tecvayli, the named-patient pathway overview covers the international framework and the United Kingdom country deep-dive covers the MHRA Specials Licence, NICE technology appraisal, NHS England Specialised Commissioning, and the dispensing infrastructure in detail. The MHRA's own guidance on the supply of unlicensed medicinal products (often called the MHRA Guidance Note 14) provides the formal regulatory framing for prescribers and pharmacists. The General Pharmaceutical Council's standards on the dispensing of unlicensed medicines provide the pharmacy practice framework.

For UK patient information on the NHS-funded pathway, the National Institute for Health and Care Excellence (NICE) publishes the relevant technology appraisal guidance, and NHS England Specialised Commissioning publishes the corresponding clinical commissioning policy. Patients can search the NICE website for the specific technology appraisal that applies to their medicine and indication.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com